

8 – 11 October, 2026
Dubrovnik, Hotel Kompas

10th Congress of the Croatian Neurosurgical Society, CroMA



PROGRAMME

www.neurosurgerycroatia26.com



INTRODUCTION

Dear colleagues, dear friends,

On behalf of the Managing Board of the Croatian Neurosurgical Society as well as of the Organizing Committee, I have the honor and pleasure of welcoming you to the **10th Congress of the Croatian Neurosurgical Society, CroMA**, which will be held from October 8 to 11, 2026 at the Kompas Hotel in Dubrovnik.

This Congress marks a special and meaningful occasion. Holding our **10th Congress** is in itself an important milestone — a moment to gather not only in professional exchange, but also in a spirit of reflection, pride, and shared purpose. As the Croatian Neurosurgical Society celebrates **34 years** of existence, we can look back with pride on a period during which much has evolved and changed in Croatian neurosurgery — and unquestionably for the better. Over these more than three decades, our profession has advanced in knowledge, technique, organization, international collaboration, and in the scope and quality of care we provide to our patients. This Congress will therefore be an opportunity not only to showcase contemporary achievements, but also to discuss, honor, and celebrate the progress of Croatian neurosurgery and the people who have helped shape it.

In a time marked by complexity, uncertainty, and the need for closer understanding across all borders, it becomes even more meaningful for professionals — especially in medicine, and particularly in a demanding discipline such as neurosurgery — to come together, share experience, and work side by side for the benefit of all humanity. In this spirit, our Congress continues its mission of building bridges across institutions, countries, continents, and professional communities. We are proud that, once again, we will bring together renowned neurosurgeons from different parts of the world and representatives of major neurosurgical associations, with the participation of the **World Federation of Neurosurgical Societies (WFNS)** standing as a particular testament to this vision, as the largest global community in neurosurgery.

This year's Congress will be further enriched by a special **Educational seminar organized by the WFNS**, as an integral part of the meeting. In addition, we are especially pleased that one day of the Congress will include a **Nursing satellite symposium**, recognizing the indispensable role of neurosurgical nursing professionals in the care of our patients and in the advancement of our field.

We are confident that the **10th Congress of the Croatian Neurosurgical Society, CroMA** will provide an outstanding setting for professional formation, exchange of ideas, and warm collegial interaction, while at the same time celebrating the journey of Croatian neurosurgery and looking ahead to its future.

Thank you for your support, and we are very much looking forward to welcoming you.

Professor **Miroslav Vukić**, MD, PhD
President of the Organizing Committee
Past President of the Croatian Neurosurgical Society, CroMA



WELCOME LETTER

Dear colleagues, dear friends,

It is my great honor and pleasure, as President of the Croatian Neurosurgical Society, to welcome you to the **10th Congress of the Croatian Neurosurgical Society, CroMA**, which will take place from October 8 to 11, 2026, at the Hotel Kompas in Dubrovnik.

This Congress represents an important moment for our Society and for Croatian neurosurgery as a whole. The tenth national congress is more than a regular professional meeting; it is a milestone that invites us to look back with respect, to recognize the achievements of those who built our specialty, and **to look forward with ambition, responsibility, and confidence.**

Over the past 34 years, the Croatian Neurosurgical Society has grown into a professional community that connects generations of neurosurgeons, supports education and scientific exchange, and represents Croatian neurosurgery within the wider European and international neurosurgical family. **Our task today is to preserve this tradition, but also to strengthen it through openness, collaboration, innovation, and care for future generations.**

The Dubrovnik Congress will bring together colleagues from Croatia, the region, Europe, and beyond. We are especially proud that the scientific program will be enriched by international participation and by an Educational Seminar organized in cooperation with the World Federation of Neurosurgical Societies. This reflects our intention to make the Congress not only a national gathering, but also a meeting place for meaningful international exchange.

I am also particularly pleased that the Congress will include a Nursing satellite symposium, emphasizing the essential role of neurosurgical nurses and multidisciplinary teamwork in modern neurosurgical care.

I sincerely hope that this Congress will be a place of high-quality scientific discussion, professional inspiration, collegial friendship, **and shared commitment to the future of neurosurgery. Dubrovnik, with its unique history, beauty, and openness to the world, provides a fitting setting for such a gathering.**

On behalf of the Croatian Neurosurgical Society, I would like to thank you very much for joining us in Dubrovnik.

Sergej Mihailović Marasanov, MD

President of the Croatian Neurosurgical Society, CroMA



ORGANIZER

Croatian Neurosurgical Society, CroMA

ENDORSED BY

World Federation of Neurosurgical Societies (WFNS)

UNDER THE AUSPICES OF

City of Dubrovnik

CONGRESS VENUE

Hotel Kompas
Dubrovnik, Croatia

ORGANIZING COMMITTEE

President: Miroslav Vukić

Members: Sergej Mihailović Marasanov, Nenad Kudelić Karlo Houra, Vlatko Ledenko, Dario Mužević,
Marina Raguž, Hrvoje Šimić, Dario Josip Živković

SCIENTIFIC COMMITTEE

Members: Miroslav Vukić, Luis A. Borba, Sergej Mihailović Marasanov, Bernard R. Bendok,
Nenad Kudelić, Jean de Oliveira

TOPICS

1. Vascular Neurosurgery
2. Spinal Neurosurgery
3. Neurooncology
4. Skull Base Surgery
5. Neurotrauma and Critical Care
6. Pediatric Neurosurgery
7. Stereotactic Neurosurgery and Radiosurgery
8. Functional, Epilepsy and Neuromodulation
9. Hydrocephalus and CSF Disorders
10. Neuroimaging, Navigation & Intraoperative Technologies
11. Free topics
12. Nursing satellite symposium



INVITED SPEAKERS

1. Jean Régis, France
2. Andreas Raabe, Switzerland
3. Uli Sure, Germany
4. Jurgén Beck, Germany
5. Bassant Misra, India
6. Bernard Bendok, USA
7. Nelson Oyesiku, USA
8. Beverly Claire Walters, USA
9. Kenan Arnautovic, USA
10. Martin Smrcka, Czech Republic
11. Volodymyr Smolanka, Ukraine
12. Roman Bosnjak, Slovenia
13. Ibrahim Omerhodžić, B&H
14. Marco Fontanella, Italy
15. Dan Barrow, USA
16. Marijan Klarica, Croatia

REGISTRATION FEES

Doctors	400,00 €
Residents	350,00 €
Nurses/Technicians	200,00 €
Exhibitor Firm Representative	250,00 €

CONGRESS AGENCY

Registration, accommodation, congress information for participants, exhibitors, advertisers, and sponsors, technical organization:

VIVID ORIGINAL Ltd.



Vivid Original

Maksimirska cesta 112A, HR-1000 Zagreb, Croatia

Contact: Goran Grbić

M +385 98 1706 028

@ goran.grbic@vivid-original.com

W www.neurosurgerycroatia26.com

W www.vivid-original.com



PROGRAMME

THURSDAY, 8 OCTOBER 2026

17:00-19:00 REGISTRATION

FRIDAY, 9 OCTOBER 2026

08:00-17:30 REGISTRATION

08:40-09:00 OPENING - Opening ceremony and welcome addresses

09:00-10:50 MORNING SESSION I - Invited lectures & HND retrospective

CHAIRS: Miroslav Vukić, Sergej Mihailović Marasanov

09:00-09:20 Andreas Raabe - EANS 2025 guidelines on the surgical treatment of intracerebral hemorrhage - invited speaker

09:20-09:40 Jean Régis - Vestibular Schwannomas multidisciplinary management: where are we heading? - invited speaker

09:40-10:00 Ulrich Sure - Modern treatment of cavernomas - invited speaker

10:00-10:20 Dan Barrow - Cavernous Malformations: How MRI, the Microscope, and the Bench Created a New Field of Practice - invited speaker

10:20-10:40 Beverly Claire Walters - Utility of Top-Quality Survey Methodology to Answer Appropriate Neurosurgery Research Questions - invited speaker

10:40-10:50 Bruno Splavski - A brief retrospective of 30 years of neurosurgical scientific congresses of the Croatian Neurosurgical Society

10:50-11:10 COFFEE BREAK

11:10-12:50 MORNING SESSION II

CHAIRS: Nenad Kudelić, Vlatko Ledenko

11:10-11:30 Jürgen Beck - Spinal CSF leaks and SIH - a novel neurosurgical realm - invited speaker

11:30-11:50 Marco Fontanella - Surgery versus endovascular treatment for spinal dural arteriovenous fistulas: A multicenter experience - invited speaker

11:50-12:10 Volodymyr Smolanka - Surgery for temporal lobe epilepsy: does it require faster decisions? - invited speaker

12:10-12:20 Goran Mrak - Microsurgical management of insular gliomas: a ten-year single-center experience



12:20-12:30 **Hrvoje Vavro** - 18F FET-PET in glioma follow-up: a game changer or just another player?

12:30-12:40 **Mia Jurilj Sajko** - Ceramide-centered metabolic reprogramming and ganglioside remodeling in human gliomas

12:40-12:50 **Marina Zmajević Schönwald** - Double mapping of the motor speech cortex using preoperative navigated TMS and intraoperative direct cortical stimulation during awake glioma surgery

12:50-14:30 **LUNCH BREAK**

14:30-15:45 **AFTERNOON SESSION I - Spine, neurotrauma & CSF disorders**
CHAIRS: Karlo Houra, Hrvoje Šimić

14:30-14:40 **Jurica Maraković** - Our experience with O-arm-based navigation in spinal neurosurgery: a 12-year single-center experience

14:40-14:50 **Karlo Houra** - Endoscopic foraminoplasty for patients with single-level foraminal stenosis of the lumbar spine

14:50-15:00 **Zlatko Kolić** - Synergistic regenerative potential of platelet-rich plasma and microfragmented adipose tissue in degenerative disc disease: a biomarker-stratified phase 2B trial

15:00-15:15 **Marijan Klarica** - Effect of craniectomy on cerebrospinal fluid pressure in different body positions in an experimental cat model - Invited Presentation

15:15-15:25 **Nenad Kudelić** - Hydrocephalus revisited: implications of contemporary CSF physiology for neurosurgical practice

15:25-15:35 **Klara Brgić Mandić** - CSF biomarker dynamics during external lumbar drainage in iNPH patients as prognostic indicators for shunt responsiveness

15:35-15:45 **Duje Vukas** - Biomarkers and microbiome signatures in idiopathic normal pressure hydrocephalus: pilot study results

15:45-16:05 **COFFEE BREAK**

16:05-17:25 **AFTERNOON SESSION II - Functional neurosurgery, epilepsy**
CHAIRS: Marina Raguz, Dario Josip Živković

16:05-16:25 **Bernard Bendok** (online) - Real-time Remote Telerobotic Magnetic Navigation for Endovascular Stroke Thrombectomy in a Simulated Mechanical Model Across 5,700 Miles - invited speaker



- 16:25-16:35** Darko Chudy - Deep Brain Stimulation in Disorders of Consciousness: Are We Setting the Agenda?
- 16:35-16:45** Jakob Nemir - Deep Brain Stimulation in pediatric patients: a single-center experience
- 16:45-16:55** Fadi Almahariq - Direct targeting in deep brain stimulation: advancing precision through modern neuroimaging and technology
- 16:55-17:05** Niko Njirić - The impact of stereo-electroencephalography on the evolution of resective epilepsy surgery: a 16-year single-center experience
- 17:05-17:15** Dominik Romić - Radiofrequency thermocoagulation for trigeminal neuralgia: our experience and a review of the literature
- 17:15-17:25** Marina Raguz - Personalized neuromodulation for refractory facial pain: from peripheral nerve to cortical and deep brain stimulation
-

SATURDAY, 10 OCTOBER 2026

08:50-17:30 REGISTRATION

09:20-09:30 OPENING - Introductory remarks, Miroslav Vukić

09:30-11:10 **WFNS NEUROONCOLOGY BLOCK I**
CHAIRS: Kenan Arnautović, Nelson Oyesiku

09:30-09:50 Jürgen Beck - Molecular neurosurgery - intraoperative decision-making for brain tumors - invited speaker

09:50-10:10 Andreas Raabe - Adjuncts in low-grade glioma surgery - invited speaker

10:10-10:30 Basant Misra - Clival Chordoma: Choosing the Right Approach - invited speaker

10:30-10:50 Kenan Arnautović - Giant and large pituitary adenomas: how to achieve gross total resection, improve vision and eliminate postoperative CSF leak - invited speaker

10:50-11:10 Nelson Oyesiku - Evolution and Revolution in Pituitary Medicine and Surgery - invited speaker

11:10-11:30 COFFEE BREAK



- 11:30-12:00** **SERVIER SPONSORED SYMPOSIUM – DIAMOND SPONSOR**
Advancing Glioma Care: Integrating Targeted Therapy into Neurosurgical Practice
Speakers: Klara Brgić Mandić; Ana Mišir Krpan
Moderator: Goran Mrak
-
- 12:00-13:00** **WFNS NEUROONCOLOGY BLOCK II**
CHAIRS: Volodymyr Smolanka, Bruno Splavski
- 12:00-12:20** Roman Bošnjak - Managing intracavernous carotid artery mobilisation to expose the lateral cavernous sinus compartment safely - invited speaker
- 12:20-12:40** Martin Smrčka - Transcranial surgery for craniopharyngiomas, contemporary concepts and surgical corridors - invited speaker
- 12:40-13:00** Ibrahim Omerhodžić - Transtentorial and transfalcine approaches for deep midline brain lesions - invited speaker
-
- 13:00-14:30** **LUNCH BREAK**
-
- 14:30-15:50** **GENERAL CONGRESS SESSION - Technology, neurooncology, pediatrics & radiosurgery**
CHAIRS: Dario Mužević, Hrvoje Šimić
- 14:30-14:40** Ilija Perutina - Frame or frameless? A five-year comparison of intracranial tumor biopsy techniques
- 14:40-14:50** Dario Josip Živković - Brain biopsy using the CIRQ robotic arm: a single-center experience
- 14:50-15:00** Sergej Mihailović Marasanov - Gamma Knife radiosurgery for WHO grade 2 meningiomas: single-centre Zagreb series
- 15:00-15:10** Vjerislav Peterković - Single-center experience of endoscopic endonasal craniopharyngioma surgery
- 15:10-15:20** Hrvoje Jednačak - Embryonal tumor with multilayered rosettes (ETMR): a single-surgeon experience
- 15:20-15:30** Miroslav Gjurašin - Neurosurgical treatment of pediatric Chiari I patients: balancing actual controversies and clinical decisions
- 15:30-15:40** Joško Bilandžić - MMA embolization as a stand-alone treatment for chronic subdural hematoma - single-centre experience
- 15:40-15:50** Ivan Pašalić - Evaluating the impact of surgery on survival in melanoma brain metastases



15:50-16:10

COFFEE BREAK

16:10-17:30

RAPID-FIRE ORAL POSTER SESSION

CHAIRS: Sergej Mihailović Marasanov, Nenad Kudelić, Marina Raguž

16:10-16:13

Hrvoje Krpina - Early experience with unilateral biportal endoscopic lumbar herniated disc decompression: impact on length of hospital stay

16:13-16:16

Vjenceslav Vrtarić - First national application of the Medtronic Mazor robotic guidance system for minimally invasive spinal instrumentation in Croatia: initial clinical experience

16:16-16:19

Toni Radić - Effect of prolonged waiting lists on surgical decision-making in patients with isolated single-level lumbar disc herniation in elective cases

16:19-16:22

Hrvoje Barić - Should cervical spinal dural arteriovenous fistulas be considered a separate entity from thoracic and lumbar ones? Evidence from a meta-analysis

16:22-16:25

Sergej Mihailović Marasanov - Craniospinal cerebrospinal fluid volume changes after cranioplasty of an exceptionally large bilateral cranial defect: a case report

16:25-16:35

DISCUSSION - Group 1: Spine, vascular & CSF

16:35-16:38

Domagoj Gajski - Transsphenoidal endoscopic surgery for pituitary gland tumors: institutional experience

16:38-16:41

Klara Brgić Mandić - Clinical outcomes in low-grade glioma patients: a 12-year retrospective study

16:41-16:44

Andrej Desnica - Longitudinal cognitive outcome in synchronous IDH-mutant CNS WHO grade 2 and grade 4 astrocytomas of the dominant hemisphere: evidence of functional reorganization

16:44-16:47

Lana Maljković - Cognitive outcomes and functional recovery following awake craniotomy in a patient with multiple sclerosis and low-grade glioma: a case study

16:47-16:50

Petar Marčinković - From cysts to PTPR: a single-center journey through the spectrum of pineal region tumors

16:50-17:00

DISCUSSION - Group 2: Neurooncology & skull base

17:00-17:03

Miroslav Gjurašin - Neurosurgical treatment of craniosynostosis in children: the importance of early diagnosis and clinical management

17:03-17:06

Ivan Konstantinović - Chronic subdural hematoma due to a ruptured arachnoid cyst in an 11-year-old boy following minor head trauma: case report and literature overview



- 17:06-17:09** Niko Njirić - Vagus nerve stimulation for pediatric drug-resistant epilepsy: a single-center experience
- 17:09-17:12** Albert Haller - Anterior thalamic deep brain stimulation for drug-resistant epilepsy: the first Croatian experience
- 17:12-17:25** **DISCUSSION - Group 3: Pediatric neurosurgery, epilepsy & neuromodulation**

17:25-17:30 **CLOSING REMARKS - Acknowledgements and congress closure**

SATURDAY, 10 OCTOBER 2026

08:00-13:00 **REGISTRATION**

08:30-08:40 **OPENING OF THE NURSING SYMPOSIUM - Welcome and introduction**

08:40-10:20 **NURSING SYMPOSIUM BLOCK I - Perioperative nursing, technology & clinical practice**

CHAIRS: Lucija Mioč, Olivera Mihordin

08:40-08:50 Lucija Mioč - Treatment options at the Department of Neurosurgery at the University Hospital Center Zagreb

08:50-09:00 Sanela Seiter - The importance of professional experience and continuous professional development in the perioperative nursing care of neurosurgical patients

09:00-09:10 Vesna Svirčević - Technological Advances in Intraoperative Neurosurgical Care

09:10-09:20 Ivana Jozić - The impact of operating room nurse experience on the duration of complex spine surgery: Practice Makes Perfect

09:20-09:30 Tomislav Radoš - Instrumentation in neurosurgical robotic-assisted spine surgery with Mazor

09:30-09:40 Iva Perić - The role of nurses in preoperative, intraoperative and postoperative care in endoscopic surgery

09:40-09:50 Marijana Rogulja - The effectiveness of epidural steroid injection in the treatment of painful spinal conditions

09:50-10:00 Patricija Škreb - Clinical manifestations, molecular mechanisms and surgical treatment of craniosynostosis

10:00-10:10 Maja Miletić - Modern treatment of medulloblastoma



10:10-10:20	Ana Uremović - Cerebrovascular diseases
10:20-10:40	MODERATED DISCUSSION - Questions, discussion and key messages from Block I
10:40-11:00	COFFEE BREAK
11:00-12:20	NURSING SYMPOSIUM BLOCK II - Neurocritical care, radiosurgery & neuromodulation <i>CHAIRS: Vesna Svirčević, Maja Miletić</i>
11:00-11:10	Maja Bespaljko - The use of the Glasgow Coma Scale in nursing practice for neurosurgical patients
11:10-11:20	Ljiljana Ešegović - Nursing care for patients during invasive neuromonitoring of patients with an acute cerebral aneurysm
11:20-11:30	Lucija Mioč - Gamma Knife radiosurgery in contemporary neurosurgical practice from a nursing perspective
11:30-11:40	Jelena Sabljak - From tumor to neuralgia: indications for Gamma Knife radiosurgery
11:40-11:50	Martina Škrlić - Safety and accuracy in Gamma Knife radiosurgery - the role of RTTs
11:50-12:00	Petra Gazilj - Nursing care of patients undergoing deep brain stimulation for drug-resistant epilepsy
12:00-12:10	Branka Gabud - Nursing management during spinal cord stimulation implantation: percutaneous and paddle lead techniques
12:10-12:20	Nikolina Filipović, Diana Dragija - The first occipital nerve stimulator implantation in Croatia - the role of the operating room scrub nurse in a novel neuromodulation procedure
12:20-12:50	PANEL DISCUSSION - Practical conclusions and take-home messages
12:50-13:00	CLOSING REMARKS - Acknowledgements and symposium closure
13:00-14:30	CONGRESS LUNCH BREAK



DIGITAL POSTERS

1. **COMPLICATIONS IN LATERAL SKULL BASE APPROACHES: LESSONS LEARNED FROM SURGICAL PRACTICE**
Goran Mrak, Jakob Nemir, Niko Njirić, Klara Brgić Mandić, Hrvoje Barić, Karlo Prižmić
2. **SHIFTING PARADIGM IN CLASSIFICATION OF TRAUMATIC BRAIN INJURY. CHALLENGES AND FUTURE PERSPECTIVES IN TREATING MODERATE BRAIN INJURIES**
Bruno Splavski
3. **ATYPICAL PRESENTATION OF MULTIPLE CYSTIC BRAIN METASTASES FROM LUNG CANCER MIMICKING BRAIN ECHINOCOCCOSIS**
Marin Lakić, Fadi Almahariq, Albert Haller, Ivan Jovanović, Anđelo Kaštelančić, Petar Marčinković, Tonko Marinović, Darko Orešković, Marina Raguz, Darko Chudy
4. **BEYOND THE ELECTRODE: BUILDING DBS CENTERS AND NEUROSURGEONS IN FUNCTIONAL NEUROSURGERY**
Fadi Almahariq, Darko Orešković, Marin Lakić, Domagoj Dlaka, Albert Haller, Petar Marčinković, Tonko Marinović
5. **CONTEMPORARY MANAGEMENT OF BRAIN ARTERIOVENOUS MALFORMATIONS: BALANCING CURE AND TREATMENT- RELATED RISK**
Goran Mrak, Jakob Nemir, Klara Brgić Mandić, Niko Njirić, Fabian Gjoni, Zara Miočić
6. **FIVE-YEAR SURVIVAL AFTER GROSS-TOTAL RESECTION OF A NEONATAL HIGH-GRADE ASTROCYTIC TUMOR: A CASE REPORT**
Karlo Prižmić, Hrvoje Jednačak
7. **MICROSURGICAL TREATMENT OF BRAINSTEM CAVERNOUS MALFORMATIONS: A SINGLE-CENTER EXPERIENCE**
Zara Miočić, Hrvoje Jednačak, Vjerislav Peterković, Andrej Desnica, Jakob Nemir, Klara Brgić Mandić, Hrvoje Barić, Niko Njirić, Fabian Gjoni, Goran Mrak
8. **SPONTANEOUS INTRAVENTRICULAR HEMORRHAGE REVEALING A LEFT TRIGONAL MENINGIOMA: CASE REPORT AND LITERATURE REVIEW**
Andrej Desnica, Niko Njirić
9. **MICROSURGICAL CLIPPING OPPOSED TO ENDOVASCULAR EMBOLIZATION IN THE TREATMENT OF MIDDLE CEREBRAL ARTERY ANEURYSMS: A COMPARATIVE REVIEW**
Bruno Splavski



10. **PARADIGM SHIFT IN SKULL BASE MENINGIOMA TREATMENT OVER THE LAST FIVE DECADES: FROM RADICAL RESECTION TO FUNCTIONAL PRESERVATION**
Goran Mrak
11. **INTRAOPERATIVE ELIMINATION OF LATERAL SPREAD RESPONSE (LSR) DURING MICROVASCULAR DECOMPRESSION FOR HEMIFACIAL SPASM: A TWO CASES EXPERIENCE**
Andrej Desnica, Ines Trninić, Niko Njirić
12. **TEMPORAL MUSCLE THICKNESS AS A SURROGATE MARKER OF SARCOPENIA IN INTRACRANIAL MENINGIOMA SURGERY: A RETROSPECTIVE STUDY**
Dario Mužević, Tomislava Tretinjak, Irina Bagić, Nikolina Šilješ
13. **MULTIDISCIPLINARY TREATMENT OF SKULL BASE TUMORS**
Domagoj Dlaka, Martin Jurlina, Dominik Romić, Marina Raguž, Jurica Maraković, Fadi Almahariq, Valentina Galkowski, Anđelo Kaštelančić, Tonko Marinović
14. **EMERGENCY MANAGEMENT OF ACUTE SPINAL EPIDURAL HEMATOMA FOLLOWING PADDLE SPINAL CORD STIMULATION IMPLANTATION: A CASE REPORT AND LITERATURE REVIEW**
Marin Lakić, Marina Raguž, Andrea Blažević, Albert Haller, Darko Orešković, Anđelo Kaštelančić, Tonko Marinović, Darko Chudy
15. **BEYOND THE IMPLANT: EVOLUTION OF A MODERN SPINAL CORD STIMULATION PROGRAM**
Marina Raguž, Petar Marčinković, Sven Krušić, Domagoj Dlaka, Damir Tomac, Andrea Blažević, Albert Haller, Marin Lakić, Fadi Almahariq, Darko Chudy, Tonko Marinović
16. **THE TRICKY TERRAIN OF TRANS-SYLVIAN INSULAR GLIOMA RESECTION: ANATOMY IS YOUR POLESTAR**
Shashwat Mishra
17. **INDIGENOUS LOW-COST 5-ALA FLUORESCENCE-GUIDED SURGERY PLATFORM FOR HIGH-GRADE GLIOMAS: A PROSPECTIVE COMPARATIVE FEASIBILITY PILOT STUDY**
Vivek Tandon, Shashwat Mishra, Vedang Mahajan, Ajay Garg, T Velpandian, Dalip Singh Mehta
18. **SKULL BASE GEOMETRY REDEFINED: A MIRROR-SYMMETRIC FIX2DISSECT CADAVERIC STUDY TO THE BASILAR APEX**
Amol Raheja, Vishal Garg, Renu Dhingra, Jessy Jp, Abhishek Yadav, Ajay Garg, William T Couldwell, Ashish Suri



19. **SAFETY AND FEASIBILITY OF PRONE POSITIONING IN PATIENTS WITH ACUTE BRAIN INJURY AND ARDS: A SINGLE-CENTER CASE SERIES**
Mateo Perić, Ana Milas, Luka Vrdoljak
20. **SYNOVIAL SARCOMA OF THE SCIATIC NERVE MIMICKING LUMBAR RADICULOPATHY**
Albert Haller, Andrea Blazevic, Dean Giroto
21. **CORRELATION BETWEEN CERVICAL SPINAL STENOSIS AND MUSCLE DEGENERATION IN THE CERVICAL PARASPINAL MUSCULATURE**
Ivan Bošnjak, Mia Smoljan, Dario Josip Živković, Manuela Frančić, Ivan Radić, Andrija Lončar
22. **USE OF THORACOLUMBAR FASCIA AUTOGRAFT IN TREATING PERSISTENT CEREBROSPINAL FLUID LEAK FOLLOWING LUMBAR DECOMPRESSION: A CASE REPORT**
Patricija Belužić, Toni Radić, Nenad Kudelić
23. **QUALITY OF LIFE IN OSTEOPROTIC PATIENTS FOLLOWING VERTEBROPLASTY FOR VETEBRAL FRACTURE**
Martina Kolačko, Andreja Vađunec
24. **INTRADURAL EXTRAMEDULLARY SCHWANNOMA OF THE THORACOLUMBAR JUNCTION (Th11-Th12): AN INCIDENTAL FINDING IN A PATIENT WITH LUMBAR RADICULOPATHY - A CASE REPORT**
Renata Runjić Šerić, Ivan Konstantinović, Željko Bušić, Vlatko Ledenko
25. **THERAPEUTIC WINDOW OR CURE: WHAT LITERATURE AND HANDS-ON PRACTICE TEACH US ABOUT SPINAL INTERVENTIONS**
Petar Marčinković, Dominik Romic, Darko Perovic, Ivica Franciskovic, Tonko Marinovic
26. **EVALUATING MINIMALLY INVASIVE SPINE SURGERY: OUR EXPERIENCE AND LITERATURE REVIEW**
Petar Marčinković, Dominik Romic, Domagoj Dlaka, Albert Haller, Marin Lakic, Damir Tomac, Vjekoslav Jelec, Tonko Marinovic
27. **RESECTING DRUG-RESISTANT EPILEPSY IN TSC: HARNESSING THE ASLEEP- AWAKE-ASLEEP APPROACH FOR PRECISION IN DELICATE BRAIN AREAS AFTER SEEG VERIFICATION OF EPILEPTIC ZONE**
Jakob Nemir, Niko Njirić, Zara Miočić, Vlatko Šulentić, Haris Mehdić, Kamelija Žarković, Goran Mrak



28. **STEREOTACTIC ASPIRATION OF THE COLLOID CYST OF THE THIRD VENTRICLE**

Anđelo Kaštelančić, Andrea Blazevic, Albert Haller, Marin Lakić, Darko Oreskovic, Fadi Almahariq, Jurica Marakovic, Damir Tomac, Darko Chudy, Tonko Marinovic

29. **SPINAL CORD STIMULATION AS TOOL FOR IMPROVING RECOVERY OF SPINAL CORD INJURY PATIENT**

Andrea Blažević, Marina Raguž, Albert Haller, Marin Lakić, Petar Marčinković, Darko Orešković, Fadi Almahariq, Domagoj Dlaka, Darko Chudy, Tonko Marinović

SPONSORS

GENERAL SPONSORS

Medtronic



DIAMOND SPONSORS



BRONZE SPONSOR



EXHIBITORS



SPONSORS





CROATIA
OSIGURANJE

Ugovori zdravstveno i treniraj mjesec dana besplatno

Popust


30€
na osiguranje

Više na crosig.hr | Ponuda vrijedi do 31.10.2026.

Generirano s UI

U bolesnika s astroцитотомom ili oligodendrogliomom gradusa 2 te mutacijom gena *IDH1/2*^{1,3}

PRECIZNO ZAUSTAVITE PROGRESIJU³




META: mIDH1/2
POKRENUTA INHIBICIJA

1. Sažetak opisa svojstava lijeka VORANIGO® travanj 2026.
2. FDA. Izvanci iz informacija o lijeku VORANIGO®.
3. Mellingshoff IK et al. N. Engl J Med. 2023;389:589-601.


▼ Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo otkrivanje novih sigurnosnih informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu za ovaj lijek. **NAZIV LIJEKA:** Voranigo 10 mg filmom obložene tablete; Voranigo 40 mg filmom obložene tablete. **SASTAV*** Voranigo 10 mg filmom obložene tablete: jedna filmom obložena tableta sadrži 10 mg vorasideniba (u obliku hemicitratne kiseline hemihidrata). Voranigo 40 mg filmom obložene tablete: jedna filmom obložena tableta sadrži 40 mg vorasideniba (u obliku hemicitratne kiseline hemihidrata). **INDIKACIJA*:** Voranigo je u monoterapiji indiciran za liječenje astrocitoma ili oligodendroglioma gradusa 2 koji uglavnom ne pokazuju postkontrastnu imbibiciju i koji su pozitivni na mutaciju R132 u genu IDH1 ili mutaciju R172 u genu IDH2 u odraslih i adolescentnih bolesnika u dobi od 12 ili više godina i tjelesne težine od najmanje 40 kg koji su prethodno podvrgnuti samo kirurškoj intervenciji i kod kojih ne postoji neposredna potreba za radioterapijom ili kemoterapijom. **DOZIRANJE I NAČIN PRIMJENE*:** Liječenje mora započeti i nadzirati liječnik koji ima iskustva s primjenom protutumorskih lijekova. Prije uvođenja lijeka Voranigo bolesnicima se odgovarajućim dijagnostičkim testom mora potvrditi prisutnost mutacije R132 u genu za izocitrat dehidrogenazu 1 (IDH1) ili mutacije R172 u genu za izocitrat dehidrogenazu 2 (IDH2). Preporučena doza lijeka Voranigo u odraslih i adolescenata u dobi od 12 ili više godina iznosi 40 mg jedanput na dan za bolesnike tjelesne težine od najmanje 40 kg. Ne mogu se dati preporuke za doziranje u bolesnika tjelesne težine manje od 40 kg zbog nedostatka kliničkih podataka u toj populaciji. Ovisno o sigurnosti i podnošljivosti lijeka u pojedinog bolesnika, možda će biti potrebno privremeno prekinuti primjenu ili smanjiti dozu lijeka **KONTRAINDIKACIJE*:** Presjetljivost na djelatne tvari ili neku od pomoćnih tvari. **POSEBNA UPOZORENJA I MJERE OPREZA*:** **Hepatotoksičnost:** Vrijednosti jetrenih enzima (uključujući ALT, AST i gama glutamiltransferazu [GGT]) i ukupnog bilirubina potrebno je odrediti prije početka liječenja, svaka 2 tjedna tijekom prva 2 mjeseca liječenja, zatim jednom mjesečno tijekom prve 2 godine liječenja, a potom kako je klinički indicirano. U slučaju povišenja vrijednosti ALT a ili AST a s $\geq 3 \times$ GGn treba razmotriti njihovo tjedno praćenje. Ovisno o težini odstupanja vrijednosti jetrenih enzima potrebno je odgovoriti primjeru lijeka, smanjiti dozu ili trajno obustaviti liječenje. **Rizik od kancerogenosti*:** Ispitivanja kancerogenosti još nisu provedena, a klinički podaci o dugoročnoj sigurnosti su nedostadni. **Žene reproduktivne dobi / kontracepcija:** Žene reproduktivne dobi moraju koristiti učinkovitu kontracepciju tijekom liječenja i još najmanje 2 mjeseca nakon primjene posljednje doze. Žene koje planiraju trudnoću treba uputiti na savjetovanje o reprodukciji. Budući da vorasidenib može smanjiti koncentracije hormonskih kontraceptiva, preporučuje se uz njih koristiti i mehaničku metodu kontracepcije tijekom liječenja i još najmanje 2 mjeseca nakon primjene posljednje doze. Muškarci trebaju prije početka liječenja potražiti savjet o zamrzavanju sperme. **Oštećenje jetrene funkcije:** Farmakokinetika i sigurnost vorasideniba nisu se ispitivale u bolesnika s oštećenjem bubrežne funkcije (eGFR ≤ 40 ml/min/1,73 m²) ili kojima je potrebna dijaliza. Vorasidenib se ne smije primjenjivati u tih bolesnika. **Pomoćne tvari:** sadrži laktazu. Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tableti, tj. zanemarive količine natrija. **INTERAKCIJE*:** Istodobna primjena vorasideniba i snažnih inhibitora CYP1A2 (fluoksamina i ciprofloksacina) može povećati plazmatsku koncentraciju vorasideniba. Tijekom liječenja vorasidenibom treba izbjegavati istodobnu primjenu snažnih inhibitora CYP1A2 i razmotriti neke druge lijekove koji nisu snažni inhibitori CYP1A2. Istodobna primjena vorasideniba i umjerenih induktora CYP1A2 (fenitoina i rifampicina) može smanjiti plazmatsku koncentraciju vorasideniba. Tijekom liječenja vorasidenibom treba razmotriti primjenu nekih drugih lijekova koji nisu umjereni induktori CYP1A2. Istodobna primjena vorasideniba i supstrata CYP2B6, CYP2C8, CYP2C9, CYP2C19 ili CYP3A4 s uskim terapijskim indeksom (uključujući, između ostaloga, amitriptilin, alfentanil, karbamazepin, ciklosporin, doksilepin, everolimus, fentanil, fosfenitoin, ifosfamid, imipramin, fenobarbital, fenitoin, pimoizid, kinidin, sirolimus, takrolimus, tamoksifen, trimipramin, valproatnu kiselinu i zafarin) može smanjiti plazmatske koncentracije tih lijekova. Istodobna primjena vorasideniba i osjetljivih supstrata CYP2B6, CYP2C8, CYP2C9, CYP2C19 ili CYP3A4 koji nemaju uzak terapijski indeks (uključujući, između ostaloga, bupropion, buspiron, celeksib, darunavir, ibuprofen, midazolam, repaglinid, sakvinavir, tiranavir i triazolam) može smanjiti plazmatske koncentracije tih lijekova. Potrebno je oprez kad se vorasidenib primjenjuje istodobno sa supstratima BCRP a (uključujući, između ostaloga, resorustatin). **PLODNOST*:** Bolesnici i bolesnice koji planiraju začeti dijete treba uputiti na savjetovanje o reprodukciji, a muškarci trebaju prije početka liječenja potražiti savjet o zamrzavanju sperme. **TRUDNOĆA I DOJENJE*:** Vorasidenib se ne smije primjenjivati u trudnica ni u žena reproduktivne dobi koje ne koriste kontracepciju. Dojenje treba prekinuti tijekom liječenja i još najmanje 2 mjeseca nakon primjene posljednje doze. **KONTRAICIJE*:** Za žene i muškarce, moraju se koristiti visokoučinkovite metode kontracepcije tijekom liječenja te dva mjeseca nakon prekida liječenja. **UTJECAJ NA SPOSOBNOST UPRAVLJANJA VOZILIMA I RADA SA STROJEVI*:** Vorasidenib ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima. **NUSPOJAVE*:** *Vrlo često:* smanjen broj trombocita, omaglica, proljev, bol u abdomenu, povišene vrijednosti alanin aminotransferaze, povišene vrijednosti aspartat aminotransferaze, povišene vrijednosti gama glutamiltransferaze, umor. *Često:* hiperglikemija, smanjen apetit, hipofosfatemija, dispneja, gastroezofagealna refluksna bolest, povišene vrijednosti alkalne fosfataze, povišene vrijednosti bilirubina u krvi. *Manje često:* zataganje jetre, autoimuni hepatitis, nekroza jetre. *Nepoznato:* oštećenje jetre uzrokovano lijekom, hepatitis akutni. **PREDOZIRANJE*:** U slučaju predoziranja toksičnost će se vjerojatno manifestirati kao pogoršanje nuspojava povezanih s vorasidenibom. Bolesnike treba pomno nadzirati i pružiti im odgovarajuću potpurnu skrb. Nema specifičnog protjeka za predoziranje vorasidenibom. **SVOJSTVA*:** Vorasidenib je inhibitor koji ciljano djeluje na mutirane enzime IDH1 i IDH2. U bolesnika s astroцитотомom ili oligodendrogliomom mutacije gena za IDH1 i IDH2 uzrokuju prekomjernu proizvodnju 2 hidroksiglutarata (2 HG) koja narušava staničnu diferencijaciju i tako pospješuje onkogenezu. Inhibicija mutiranih proteina IDH1 i IDH2 vorasidenibom blokira abnormalnu proizvodnju 2 HG a, što dovodi do diferencijacije zloćudnih stanica i smanjenja njihove proliferacije. **NAČIN I MJEŠTO IZDAVANJA:** Na recept, u ljekarni. **VELIČINA PAKIRANJA*:** Pakiranje sadrži 30 filmom obloženih tableta. **NOŠITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET:** Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes cedex, Francuska. www.servier.com. **PREDSTAVNIK NOŠITELJA ODOBRENJA:** Servier Pharma d.o.o., Ulica Grge Tuškana 37, 10000 Zagreb. **BRJOJEVI ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET:** Voranigo 10 mg filmom obložene tablete: EU/1/25/1912/001; Voranigo 40 mg filmom obložene tablete: EU/1/25/1912/002.

*Za sve obavijesti o lijeku molimo vidjeti zadnji odobreni Sažetak opisa svojstava lijeka i uputu o lijeku.

Every closure matters



This is practice and purpose coming together
to advance the future of wound closure.



We obsess over every
detail in every suture,
every adhesive, and every
closure—to achieve
recoveries where fewer
complications occur.



See how STRATAFIX™ Knotless
Tissue Control Devices &
DERMABOND™ Portfolio^M can
work for your patients.

Please refer always to the Instructions for Use / Package Insert that come with the device for the most current and complete instructions.

This publication is not intended for distribution outside of the EMEA region.
Not all products may currently be available in all markets.

Johnson & Johnson Medical GmbH Robert-Koch-Str. 1 22851 Norderstedt, Germany

www.jnjmedtech.com

© Johnson & Johnson and its affiliates 2025. EM_SRG_WOUN_401394

NOTES

[illegible]

NOTES

This image shows a single page of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page, leaving small margins at the top and bottom. There are no vertical margin lines, no text, and no other markings on the page. It appears to be a standard piece of notebook paper.

NOTES

[illegible]



Vivid Original Ltd. Maksimirska 112a, HR-10000 Zagreb
Contact Goran Grbić **Phone** +385 98 1706 028
Mail goran.grbic@vivid-original.com **Web** vivid-original.com